MARKET

BLRX

BLRX

BioLine RX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.830
+0.550
+42.97%
After Hours: 1.800 -0.03 -1.64% 17:09 04/07 EDT
OPEN
1.400
PREV CLOSE
1.280
HIGH
1.990
LOW
1.400
VOLUME
567.78K
TURNOVER
--
52 WEEK HIGH
6.75
52 WEEK LOW
1.061
MARKET CAP
17.94M
P/E (TTM)
-0.7020
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BLRX stock price target is 11.33 with a high estimate of 18.00 and a low estimate of 5.00.

EPS

BLRX News

More
  • BioLineRx up big ahead of key data readout
  • seekingalpha · 5h ago
  • CIM, GLNG, TWO and LADR among midday movers
  • Seeking Alpha - Article · 10h ago
  • BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/12 16:42
  • biolinerx EPS beats by $2.14
  • seekingalpha · 03/12 16:06

Industry

Biotechnology & Medical Research
-2.20%
Pharmaceuticals & Medical Research
-1.62%

Hot Stocks

Symbol
Price
%Change

About BLRX

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.
More

Webull offers kinds of BioLineRX Ltd. stock information, including NASDAQ:BLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLRX stock news, and many more online research tools to help you make informed decisions.